REGENERON PHARMACEUTICALS, INC.

REGN

REGENERON PHARMACEUTICALS, INC.

REGN

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-05-01Shares Purchased (TTM):0Shares Sold (TTM):13,265

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:79,587,494Shares Outstanding:104,000,000Institutional Ownership Pct.:76.53%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Common Stock	-2	103	104	101	0	2	0	0	0	2	0	0
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	2,456	2,963	3,118	2,506	1,996	3,090	2,488	2,012	1,921	2,602	2,730	2,152
Marketable Securities Current	5,539	5,791	5,487	5,937	5,474	5,259	6,524	7,785	7,888	7,918	8,115	7,761
Accounts Receivable Net Current	6,565	5,731	5,741	5,687	5,610	5,561	6,212	6,107	5,717	5,222	5,667	5,585
Inventory Net	3,084	3,104	3,201	3,254	3,206	3,192	3,087	3,018	2,874	2,715	2,581	2,562
Prepaid Expense And Other Assets Current	802	621	475	596	574	469	349	412	682	415	387	575
Assets Current	18,446	18,209	18,022	17,981	16,860	17,572	18,661	19,334	19,082	18,872	19,479	18,635
Marketable Securities Noncurrent	9,828	9,786	10,261	10,286	10,058	9,276	8,900	8,491	7,722	6,979	5,397	5,779
Property Plant And Equipment And Finance Lease Rig…	5,459	5,266	5,120	5,002	4,841	4,694	4,600	4,439	4,306	4,226	4,146	4,006
Intangible Assets Net Excluding Goodwill	1,310	1,287	1,257	1,381	1,352	1,167	1,149	1,120	1,102	1,059	1,039	1,017
Deferred Income Tax Assets Net	4,381	4,191	4,077	3,847	3,572	3,443	3,314	3,015	2,881	2,765	2,575	2,317
Other Assets Noncurrent	2,306	2,130	1,821	1,673	1,537	1,393	1,136	1,043	994	470	444	410
Assets	41,731	40,869	40,559	40,169	38,219	37,545	37,759	37,442	36,087	34,370	33,080	32,163
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1,159	1,027	939	904	724	706	790	497	562	671	607	537
Accrued Liabilities And Other Liabilities	2,967	2,724	2,876	2,976	2,461	2,242	2,527	2,537	2,361	2,393	2,358	2,645
Finance Lease Liability Current	720	720	-	-	-	-	-	-	-	-	-	-
Contract With Customer Liability Current	685	636	553	546	482	619	628	627	586	517	459	417
Liabilities Current	5,531	5,108	4,368	4,425	3,667	3,567	3,944	3,661	3,509	3,581	3,423	3,599
Long Term Debt Noncurrent	1,987	1,986	1,986	1,986	1,985	1,985	1,984	1,984	1,984	1,983	1,983	1,983
Finance Lease Liability Noncurrent	0	0	720	720	720	720	720	720	720	720	720	720
Contract With Customer Liability Noncurrent	220	225	209	219	206	212	186	207	206	186	127	125
Other Liabilities Noncurrent	2,282	2,126	2,019	1,862	1,702	1,674	1,571	1,544	1,463	909	854	832
Liabilities	10,019	9,445	9,302	9,212	8,280	8,158	8,406	8,116	7,881	7,379	7,107	7,259
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	14,701	14,401	13,995	13,787	13,491	13,192	12,856	12,703	12,317	11,943	11,354	11,252
Retained Earnings Accumulated Deficit	37,621	36,424	35,797	35,046	33,680	32,384	31,673	30,755	29,415	27,982	27,260	26,101
Accumulated Other Comprehensive Income Loss Net Of…	-36	12	78	69	53	29	-8	60	-70	-77	-81	-177
Treasury Stock Common Value	-20,575	-19,414	-18,613	-17,944	-17,285	-16,218	-15,167	-14,192	-13,456	-12,857	-12,560	-12,271
Stockholders Equity	31,711	31,424	31,257	30,958	29,939	29,388	29,354	29,326	28,206	26,991	25,973	24,904
Liabilities And Stockholders Equity	41,731	40,869	40,559	40,169	38,219	37,545	37,759	37,442	36,087	34,370	33,080	32,163
Common Class A	0	2	2	0	0	2	0	0	0	2	0	0
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	30	30	30	30	30	30	30	30	30	30	30	30
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Common Shares	36	35	34	33	32	30	28	27	26	26	26	25

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.78%	-11.00%	-1.26%	-	-	-	-	-	-	-	-	-
2025	3.57%	-10.27%	-4.50%	5.64%	6.09%	3.59%	15.64%	17.49%	12.14%	0.97%	-4.70%	-2.91%
2024	5.06%	12.32%	13.44%	9.70%	4.75%	-9.37%	-11.95%	-16.27%	-18.69%	-2.38%	-10.96%	-15.81%
2023	-	-	-	7.63%	6.92%	4.80%	-2.50%	3.41%	14.00%	4.97%	2.79%	-5.67%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.34	3.57	4.13	4.06	4.60	4.93	4.73	5.28	5.44	5.27	5.69	5.18
Quick Ratio	2.63	2.84	3.28	3.19	3.57	3.90	3.86	4.34	4.43	4.40	4.82	4.31
Working Capital	12.92B	13.10B	13.65B	13.56B	13.19B	14.01B	14.72B	15.67B	15.57B	15.29B	16.06B	15.04B
Leverage & Debt
Debt to Equity	0.32	0.30	0.30	0.30	0.28	0.28	0.29	0.28	0.28	0.27	0.27	0.29
Interest Coverage TTM	69.37	75.61	81.69	87.61	104.94	80.15	72.30	63.07	58.28	54.17	55.44	58.54
Debt Ratio	0.24	0.23	0.23	0.23	0.22	0.22	0.22	0.22	0.22	0.21	0.21	0.23
Efficiency & Turnover
Asset Turnover TTM	0.39	0.38	0.37	0.37	0.38	0.39	0.40	0.40	0.40	0.41	0.42	0.44
Days Sales Outstanding TTM	143.04	138.13	152.09	151.07	145.43	139.71	152.65	154.09	146.64	144.06	152.99	155.13
Receivables Turnover TTM	2.55	2.64	2.40	2.42	2.51	2.61	2.39	2.37	2.49	2.53	2.39	2.35
Per Share Metrics
Diluted EPS TTM	40.84	41.07	41.48	42.71	41.06	40.46	38.34	40.06	37.45	33.52	34.77	35.19
Free Cash Flow Per Share TTM	36.58	39.55	39.01	40.75	36.67	29.07	33.96	31.82	30.79	37.71	36.32	43.32
Dividend Per Share TTM	3.68	3.60	3.54	2.68	1.77	0.88	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	91.41%	91.63%	92.05%	91.94%	92.05%	92.10%	92.34%	92.29%	92.37%	92.64%	92.89%	92.92%
Operating Profit Margin TTM	24.74%	24.32%	24.95%	25.89%	27.02%	27.20%	28.10%	28.69%	28.95%	29.40%	30.85%	32.23%
Net Profit Margin TTM	27.86%	29.65%	31.41%	32.13%	31.37%	31.94%	31.07%	33.61%	32.04%	29.45%	30.14%	30.47%
Growth Metrics
Net Revenue Growth (1Y)	9.29%	5.92%	0.99%	2.89%	5.38%	7.52%	8.27%	5.72%	6.46%	5.90%	7.76%	-4.47%
Net Income Growth (1Y)	-2.91%	-1.69%	2.09%	-1.64%	3.17%	16.63%	11.61%	16.62%	0.53%	-7.77%	-8.87%	-25.68%
EPS Growth (1Y)	-0.74%	0.87%	5.31%	2.63%	6.11%	17.83%	10.37%	14.68%	-0.49%	-8.37%	-8.53%	-25.26%
Valuation Metrics
P/E TTM	14.79	18.12	17.85	12.66	12.29	14.92	17.26	24.19	26.04	26.64	23.48	21.71
P/B TTM	2.02	2.55	2.57	1.87	1.83	2.28	2.59	3.84	3.99	3.81	3.57	3.48
P/S TTM	4.12	5.37	5.61	4.07	3.86	4.77	5.36	8.13	8.34	7.85	7.08	6.62
Market Cap	64.03B	80.14B	80.43B	57.95B	54.81B	67.13B	76.14B	112.58B	112.55B	102.79B	92.84B	86.66B
Enterprise Value	64.27B	79.88B	79.29B	57.43B	54.78B	66.02B	75.64B	112.55B	112.61B	102.16B	92.08B	86.49B
Calculated Values
Free Cash Flow TTM	3.76B	4.11B	4.08B	4.22B	3.85B	3.10B	3.66B	3.44B	3.33B	4.06B	3.88B	4.60B
Net Debt	240.60M	-264.40M	-1.14B	-527.60M	-30.50M	-1.11B	-504.60M	-27.80M	55.40M	-626.50M	-754.90M	-177.60M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-01Sale

Owner: Ryan, Arthur F

Title: -

Shares: 100

Price/Share: $707.47

Value: $70,747.00

Shares Owned: 17,503

Relationship: Director

Ownership: Direct

2026-04-01Sale

Owner: Ryan, Arthur F

Title: -

Shares: 100

Price/Share: $775.54

Value: $77,554.00

Shares Owned: 17,603

Relationship: Director

Ownership: Direct

2026-03-02Sale

Owner: Ryan, Arthur F

Title: -

Shares: 100

Price/Share: $783.52

Value: $78,352.00

Shares Owned: 17,703

Relationship: Director

Ownership: Direct

2026-02-19Sale

Owner: Zoghbi, Huda Y

Title: -

Shares: 1,638

Price/Share: $781.40

Value: $1,279,933.20

Shares Owned: 1,703

Relationship: Director

Ownership: Direct

2026-02-09Sale

Owner: Ryan, Arthur F

Title: -

Shares: 100

Price/Share: $781.51

Value: $78,151.00

Shares Owned: 17,803

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-01	Ryan, Arthur F	Director	-	Direct	Sale	100	707.47	$70,747.00	17,503	4
2026-04-01	Ryan, Arthur F	Director	-	Direct	Sale	100	775.54	$77,554.00	17,603	4
2026-03-02	Ryan, Arthur F	Director	-	Direct	Sale	100	783.52	$78,352.00	17,703	4
2026-02-19	Zoghbi, Huda Y	Director	-	Direct	Sale	1,638	781.40	$1,279,933.20	1,703	4
2026-02-09	Ryan, Arthur F	Director	-	Direct	Sale	100	781.51	$78,151.00	17,803	4
2026-02-09	Pitofsky, Jason	Officer	SVP Controller	Direct	Sale	2,036	780.50	$1,589,098.00	4,272	4
2026-01-07	Bassler, Bonnie L	Director	-	Direct	Sale	1,500	800.00	$1,200,000.00	1,703	4
2025-11-20	Bassler, Bonnie L	Director	-	Direct	Sale	760	750.00	$570,000.00	1,548	4
2025-11-07	Pitofsky, Jason	Officer	VP Controller	Direct	Sale	431	651.43	$280,766.33	4,233	4
2025-10-29	Poon, Christine A	Director	-	Direct	Sale	6,500	654.92	$4,256,980.00	2,352	4
2024-11-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,000	844.61	$844,610.00	12,931	4
2024-10-01	Ryan, Arthur F	Director	-	Direct	Sale	100	1049.73	$104,973.00	17,582	4
2024-10-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,000	1054.06	$1,054,060.00	12,931	4
2024-09-03	Ryan, Arthur F	Director	-	Direct	Sale	100	1179.76	$117,976.00	17,682	4
2024-09-03	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,000	1178.73	$1,178,730.00	12,931	4
2024-08-28	Fenimore, Christopher R.	Officer	SVP Finance & CFO	Indirect	Sale	5,680	1205.76	$6,848,716.80	0	4
2024-08-15	Poon, Christine A	Director	-	Direct	Sale	10,838	1158.39	$12,554,630.82	2,172	4
2024-08-15	Bassler, Bonnie L	Director	-	Direct	Sale	756	1170.00	$884,520.00	1,382	4
2024-08-14	Murphy, Andrew J	Officer	EVP Research	Direct	Sale	6,363	1150.69	$7,321,840.47	48,306	4
2024-08-08	Stahl, Neil	Officer	EVP Research and Development	Direct	Sale	5,197	1084.01	$5,633,599.97	50,999	4
2024-08-07	Pitofsky, Jason	Officer	VP Controller	Direct	Sale	487	1070.00	$521,090.00	4,204	4
2024-08-02	Bassler, Bonnie L	Director	-	Direct	Sale	756	1115.00	$842,940.00	1,382	4
2024-08-01	Ryan, Arthur F	Director	-	Direct	Sale	1	1100.03	$1,100.03	17,782	4
2024-08-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,137	1060.86	$1,206,197.82	12,931	4
2024-07-11	Larosa, Joseph J	Officer	EVP General Counsel and Secret	Direct	Sale	1,866	1088.95	$2,031,980.70	37,937	4
2024-07-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,137	1047.11	$1,190,564.07	12,931	4
2024-07-01	Ryan, Arthur F	Director	-	Direct	Sale	100	1059.06	$105,906.00	17,882	4
2024-06-24	Bassler, Bonnie L	Director	-	Direct	Sale	756	1062.00	$802,872.00	1,382	4
2024-06-14	Brown, Michael S	Director	-	Direct	Sale	1,535	1040.00	$1,596,400.00	1,382	4
2024-06-12	Schleifer, Leonard S	Director,Officer	Bd. Co-Chair, President & CEO	Indirect	Sale	16,149	1019.06	$16,456,799.94	0	4
2024-06-06	Schleifer, Leonard S	Director,Officer	Bd. Co-Chair, President & CEO	Indirect	Sale	787	1015.02	$798,820.74	64,198	4
2024-06-05	Bassler, Bonnie L	Director	-	Direct	Sale	827	1011.00	$836,097.00	1,382	4
2024-06-03	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,138	980.16	$1,115,422.08	12,931	4
2024-06-03	Ryan, Arthur F	Director	-	Direct	Sale	100	991.02	$99,102.00	17,982	4
2024-05-28	Brown, Michael S	Director	-	Direct	Sale	1,172	974.86	$1,142,535.92	1,382	4
2024-05-21	Larosa, Joseph J	Officer	EVP General Counsel and Secret	Direct	Sale	1,865	994.90	$1,855,488.50	34,678	4
2024-05-17	Schleifer, Leonard S	Director,Officer	Bd. Co-Chair, President & CEO	Direct	Sale	22,830	979.64	$22,365,181.20	466,877	4
2024-05-16	Yancopoulos, George	Director,Officer	Bd. Co-Chair, President & CSO	Direct	Sale	50,000	972.93	$48,646,500.00	786,383	4
2024-05-15	Schleifer, Leonard S	Director,Officer	Bd. Co-Chair, President & CEO	Direct	Sale	10,941	984.03	$10,766,272.23	397,259	4
2024-05-15	Yancopoulos, George	Director,Officer	Bd. Co-Chair, President & CSO	Direct	Sale	50,000	977.45	$48,872,500.00	836,383	4
2024-05-01	Ryan, Arthur F	Director	-	Direct	Sale	100	901.47	$90,147.00	18,082	4
2024-05-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	250	889.41	$222,352.50	12,931	4
2024-04-01	Ryan, Arthur F	Director	-	Direct	Sale	100	961.56	$96,156.00	18,182	4
2024-04-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	250	964.73	$241,182.50	13,181	4
2024-03-14	Murphy, Andrew J	Officer	EVP Research	Direct	Sale	5,783	958.88	$5,545,203.04	48,306	4
2024-03-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	358	967.50	$346,365.00	13,431	4
2024-03-01	Ryan, Arthur F	Director	-	Direct	Sale	100	978.23	$97,823.00	18,282	4
2024-02-26	Larosa, Joseph J	Officer	EVP General Counsel and Secret	Direct	Sale	1,000	990.00	$990,000.00	36,543	4
2024-02-26	Bassler, Bonnie L	Director	-	Direct	Sale	854	979.25	$836,279.50	1,382	4
2024-02-26	Sing, George L	Director	-	Direct	Sale	1,000	992.50	$992,500.00	26,349	4
2024-02-23	Sing, George L	Director	-	Direct	Sale	500	985.00	$492,500.00	26,349	4
2024-02-22	Larosa, Joseph J	Officer	EVP General Counsel and Secret	Direct	Sale	1,000	967.65	$967,650.00	37,543	4
2024-02-14	Van, Plew Daniel P	Officer	EVP & General Mgr, Industrial	Direct	Sale	10,434	944.53	$9,855,226.02	20,378	4
2024-02-09	Sing, George L	Director	-	Direct	Sale	500	955.00	$477,500.00	26,349	4
2024-02-09	Fenimore, Christopher R.	Officer	SVP Finance & CFO	Direct	Sale	4,919	952.92	$4,687,413.48	14,372	4
2024-02-07	Larosa, Joseph J	Officer	EVP General Counsel and Secret	Direct	Sale	1,000	950.00	$950,000.00	38,543	4
2024-02-07	Stahl, Neil	Officer	EVP Research and Development	Direct	Sale	8,037	950.41	$7,638,445.17	52,019	4
2024-02-05	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,000	934.71	$934,710.00	13,789	4
2024-02-01	Ryan, Arthur F	Director	-	Direct	Sale	100	952.51	$95,251.00	18,382	4
2024-02-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	273	945.61	$258,151.53	14,789	4
2024-01-30	Bassler, Bonnie L	Director	-	Direct	Sale	827	959.00	$793,093.00	1,382	4
2024-01-23	Goldstein, Joseph L	Director	-	Direct	Sale	2,707	950.00	$2,571,650.00	6,382	4
2024-01-03	Bassler, Bonnie L	Director	-	Direct	Sale	826	914.00	$754,964.00	1,382	4
2024-01-02	Ryan, Arthur F	Director	-	Direct	Sale	100	895.69	$89,569.00	18,347	4
2024-01-02	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	274	873.91	$239,451.34	15,062	4
2024-01-02	Yancopoulos, George	Director,Officer	Bd. Co-Chair, President & CSO	Indirect	Sale	16,848	900.00	$15,163,200.00	180,000	4
2024-01-02	Zoghbi, Huda Y	Director	-	Direct	Sale	1,117	900.00	$1,005,300.00	1,247	4
2024-01-02	Yancopoulos, George	Director,Officer	Bd. Co-Chair, President & CSO	Indirect	Sale	16,848	900.00	$15,163,200.00	180,000	4
2023-12-27	Brown, Michael S	Director	-	Direct	Sale	2,049	898.00	$1,840,002.00	1,247	4
2023-12-27	Fenimore, Christopher R.	Officer	SVP Controller	Direct	Sale	2,448	856.71	$2,097,226.08	14,372	4
2023-12-22	Fenimore, Christopher R.	Officer	SVP Controller	Direct	Sale	250	846.27	$211,567.50	16,820	4
2023-12-13	Bassler, Bonnie L	Director	-	Direct	Sale	610	870.00	$530,700.00	1,247	4
2023-12-11	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	270	838.44	$226,378.80	20,814	4
2023-12-05	Murphy, Andrew J	Officer	EVP Research	Direct	Sale	6,536	816.00	$5,333,376.00	59,421	4
2023-12-01	Ryan, Arthur F	Director	-	Direct	Sale	100	818.55	$81,855.00	18,447	4
2023-11-14	Murphy, Andrew J	Officer	EVP Research	Direct	Sale	6,492	800.35	$5,195,872.20	59,421	4
2023-11-07	Ryan, Arthur F	Director	-	Direct	Sale	100	828.90	$82,890.00	18,547	4
2023-11-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,000	783.91	$783,910.00	19,803	4
2023-10-13	Zoghbi, Huda Y	Director	-	Direct	Sale	1,000	850.00	$850,000.00	1,247	4
2023-10-02	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	1,038	827.00	$858,426.00	19,803	4
2023-09-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	250	834.55	$208,637.50	19,803	4
2023-08-24	Van, Plew Daniel P	Officer	EVP & General Mgr, Industrial	Direct	Sale	6,197	839.93	$5,205,046.21	21,508	4
2023-08-23	Poon, Christine A	Director	-	Direct	Sale	12,280	839.53	$10,309,428.40	2,037	4
2023-08-23	Landry, Robert E	Officer	EVP Finance CFO	Direct	Sale	223	844.00	$188,212.00	31,699	4
2023-08-22	Stahl, Neil	Officer	EVP Research and Development	Direct	Sale	11,665	841.37	$9,814,581.05	53,100	4
2023-08-21	Bassler, Bonnie L	Director	-	Direct	Sale	853	829.00	$707,137.00	1,247	4
2023-08-10	Bassler, Bonnie L	Director	-	Direct	Sale	853	789.00	$673,017.00	1,247	4
2023-08-01	Ryan, Arthur F	Director	-	Direct	Sale	100	737.75	$73,775.00	18,647	4
2023-08-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	250	744.66	$186,165.00	20,053	4
2023-07-03	Ryan, Arthur F	Director	-	Direct	Sale	100	715.83	$71,583.00	18,747	4
2023-07-03	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	250	710.09	$177,522.50	20,303	4
2023-06-01	Mccourt, Marion	Officer	EVP Commercial	Direct	Sale	250	736.00	$184,000.00	20,553	4
2023-06-01	Ryan, Arthur F	Director	-	Direct	Sale	100	734.44	$73,444.00	18,847	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

76.53%

Inst. Shares: 79,587,494

Shares Outstanding: 104,000,000

2025-12-31

80.61%

Inst. Shares: 84,313,468

Shares Outstanding: 104,600,000

2025-09-30

80.79%

Inst. Shares: 83,697,543

Shares Outstanding: 103,600,000

2025-06-30

81.36%

Inst. Shares: 85,506,071

Shares Outstanding: 105,100,000

2025-03-31

79.69%

Inst. Shares: 85,030,354

Shares Outstanding: 106,700,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	79,587,494	104,000,000	76.53%
2025-12-31	84,313,468	104,600,000	80.61%
2025-09-30	83,697,543	103,600,000	80.79%
2025-06-30	85,506,071	105,100,000	81.36%
2025-03-31	85,030,354	106,700,000	79.69%
2024-12-31	86,590,195	107,900,000	80.25%
2024-09-30	86,766,164	108,100,000	80.26%
2024-06-30	89,101,592	108,100,000	82.43%
2024-03-31	86,457,660	107,800,000	80.20%
2023-12-31	86,321,422	106,700,000	80.90%
2023-09-30	83,580,947	106,300,000	78.63%
2023-06-30	84,326,913	107,000,000	78.81%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

REGENERON PHARMACEUTICALS, INC. (REGN) — SEC Financial Statements & Analysis

REGENERON PHARMACEUTICALS, INC. (REGN) is a pharmaceutical preparations company, incorporated in NY. REGENERON PHARMACEUTICALS, INC. trades on Nasdaq as: REGN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), REGENERON PHARMACEUTICALS, INC. reported a 9.29% year-over-year revenue growth, a Gross Profit Margin of 91.41% (TTM), a Debt-to-Equity ratio of 0.32x, a Price-to-Sales (P/S) ratio of 4.12x (TTM), a Price-to-Book (P/B) ratio of 2.02x (TTM), at a market cap of $64.03B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 9.29%
Gross Profit Margin TTM: 91.41%
Debt To Equity: 0.32x
P/S TTM: 4.12x
P/B TTM: 2.02x
Market Cap: $64.03B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is REGENERON PHARMACEUTICALS, INC. in?

REGENERON PHARMACEUTICALS, INC. (REGN) operates in the Pharmaceutical Preparations industry.

What is REGN's market cap?

REGENERON PHARMACEUTICALS, INC. (REGN) has a market capitalization of $64.03B as of 2026-06-30.

What is REGN's P/E ratio?

REGENERON PHARMACEUTICALS, INC. (REGN)'s trailing twelve month P/E ratio is 14.79x as of 2026-06-30.

What exchange does REGN trade on?

REGENERON PHARMACEUTICALS, INC. (REGN) trades on the Nasdaq.

Where is REGENERON PHARMACEUTICALS, INC. incorporated?

REGENERON PHARMACEUTICALS, INC. is incorporated in NY.